Journal ArticleDOI
New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B.
Roopa Rai,Jerome Deval +1 more
Reads0
Chats0
TLDR
The current understanding of the structure and functions of NS4B, an essential component of the replication machinery of HCV, are summarized and the recent developments in anti-NS4B drug discovery open the possibility for future combination therapies with other DAAs.About:
This article is published in Antiviral Research.The article was published on 2011-05-01. It has received 63 citations till now. The article focuses on the topics: Hepatitis C virus & Pegylated interferon.read more
Citations
More filters
Journal ArticleDOI
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
TL;DR: Ongoing and future trials will determine the best antiviral combinations and whether the current seemingly rich pipeline is sufficient for successful treatment of all patients in the face of major challenges, such as HCV diversity, viral resistance, the influence of host genetics, advanced liver disease and other co-morbidities.
Journal ArticleDOI
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
TL;DR: Insight into the structures of these proteins and the mechanisms by which they contribute to the HCV replication cycle are reviewed, and how these insights have facilitated the development of new, directly acting antiviral compounds that have started to enter the clinic are discussed.
Book ChapterDOI
Hepatitis C virus proteins: from structure to function
Darius Moradpour,François Penin +1 more
TL;DR: This review summarizes current knowledge of the structure and function of the HCV proteins and highlights recent advances in the field.
Journal ArticleDOI
In Vitro Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor miR-122
Søren Ottosen,Todd B. Parsley,Lu Yang,K. Zeh,Leen-Jan van Doorn,Eva van der Veer,Anneke K. Raney,Michael R. Hodges,Amy K. Patick +8 more
TL;DR: Miravirsen is a β-doxy-locked nucleic acid-modified phosphorothioate antisense oligonucleotide targeting the liver-specific microRNA-122 (miR-122).
Journal ArticleDOI
New horizons in hepatitis C antiviral therapy with direct-acting antivirals.
TL;DR: Future research will need to define well‐tolerated and cost‐effective DAA combinations that provide the highest rates of viral eradication in all patients (including those with advanced liver disease), the broadest spectrum of action on viral genotypes showing minimal or no clinical resistance, and the shortest treatment duration.
References
More filters
Journal ArticleDOI
Global epidemiology of hepatitis C virus infection
TL;DR: Because there is no vaccine and no post-exposure prophylaxis for HCV, the focus of primary prevention efforts should be safer blood supply in the developing world, safe injection practices in health care and other settings, and decreasing the number of people who initiate injection drug use.
Journal ArticleDOI
Peginterferon alfa-2a in patients with chronic hepatitis C.
Stefan Zeuzem,S.V. Feinman,Jens Rasenack,E.J. Heathcote,M.-Y. Lai,Edward Gane,John O'Grady,J Reichen,Moisés Diago,A. Lin,Joseph Hoffman,M.J. Brunda +11 more
TL;DR: In patients with chronic hepatitis C, a regimen of peginterferon alfa-2a given once weekly is more effective than a regimen that has sustained absorption, a slower rate of clearance, and a longer half-life than unmodified interferonAlfa- 2a.
Journal ArticleDOI
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Min Gao,Richard E. Nettles,Makonen Belema,Lawrence B. Snyder,Van N. Nguyen,Robert A. Fridell,Michael H. Serrano-Wu,David R. Langley,Jin-Hua Sun,Donald R. O'Boyle,Julie A. Lemm,Chunfu Wang,Jay O. Knipe,Caly Chien,Richard J. Colonno,Dennis M. Grasela,Nicholas A. Meanwell,Lawrence G. Hamann +17 more
TL;DR: These results provide the first clinical validation of an inhibitor of HCV NS5A, a protein with no known enzymatic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations ofHCV inhibitors.
Journal ArticleDOI
Expression of Hepatitis C Virus Proteins Induces Distinct Membrane Alterations Including a Candidate Viral Replication Complex
Denise Egger,Benno Wölk,Rainer Gosert,Rainer Gosert,Leonardo Bianchi,Hubert E. Blum,Darius Moradpour,Kurt Bienz +7 more
TL;DR: It is proposed that the membranous web forms the viral replication complex in HCV-infected cells.
Journal ArticleDOI
Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome
Harvey J. Alter,Leonard B. Seeff +1 more
TL;DR: The view is concluded that severe, life-threatening, progressive liver disease clearly occurs in a sizable minority of chronically infected persons but it is speculated that fibrosis progression is neither linear or inevitable and hence that most hepatitis C virus carriers will have either a stable nonprogressive course or such indolent progression that they will die from an unrelated disease before the severe sequelae of hepatitis C become manifest.